COLLEGIUM PHARMAC.DL-,001

Collegium Pharmaceutical has agreed on an accelerated share repurchase (ASR) worth $50 million with Jefferies and received an initial delivery of about 1.56 million shares, roughly 80% of the expected amount. The ASR is part of an approved $150 million buyback program; after this tranche $100 million remain for further repurchases. CEO Vikram Karnani describes the move as a reflection of the company’s solid financial position; the company recently reported Q2 net revenue of about $199.9 million (+6%) and reaffirmed its 2026 guidance of $805–825 million, after which the stock rose in premarket trading and analysts continue to hold a consensus “buy” rating with an average price target of $53.60. » More on de.investing.com

Collegium Pharmaceutical’s shares hit a 52-week low of $30.11. In the second quarter the company beat expectations with adjusted earnings of $1.92 per share but narrowly missed revenue at $199.9 million and reported strain in its pain portfolio. Collegium raised its full-year revenue guidance to $825–855 million; the ADHD business grew significantly (JORNAY PM +41% to $46.1 million, AZSTARYS $12.9 million) and adjusted EBITDA increased to $113.8 million. Analysts view the stock as undervalued (low P/E, PEG 0.5) according to InvestingPro, while investors react to revenue pressure and portfolio risks. » More on de.investing.com

Collegium Pharmaceutical reported adjusted earnings per share of $1.76 for Q1 2026 versus $1.63 expected and revenue of $193.5 million (expectation $187.37 million). Revenue growth of 9% was driven mainly by Jornay PM (sales up 36%). The company announced the planned acquisition of AZSTARYS and confirmed full-year revenue guidance of $805–825 million (excluding acquisition effects). After the announcement the stock rose about 3.5% in premarket trading. » More on de.investing.com